The Choice of Resin-Bound Ligand Affects the Structure and Immunogenicity of Column-Purified Human Papillomavirus Type 16 Virus-Like Particles
Figure 6
Immunization Protocol-2 Anti-HPV16 L1 IgG and neutralization antibody titers.
The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers of the PBS-, hHPV16 VLP- and cHPV16 VLP-immunization groups are presented in panels A and B, respectively. For the immunizations, the mice were subcutaneously injected three times with 100 µl of PBS, 1000 ng of hHPV16 VLP or 1000 ng of cHPV16 VLP at two-week intervals (protocol-2 in Table 2). The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers were determined by ELISA and SEAP-based neutralization assays, respectively. The data values of seven individual mice (n = 7) are represented with dots. The horizontal bars indicate the median titers of the anti-HPV16 L1 IgG and neutralization antibodies.